| __timestamp | Genmab A/S | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 44820000 |
| Thursday, January 1, 2015 | 91224000 | 82080000 |
| Friday, January 1, 2016 | 102413000 | 97130000 |
| Sunday, January 1, 2017 | 146987000 | 121271000 |
| Monday, January 1, 2018 | 213695000 | 153548000 |
| Tuesday, January 1, 2019 | 342000000 | 202541000 |
| Wednesday, January 1, 2020 | 661000000 | 245164000 |
| Friday, January 1, 2021 | 1283000000 | 285773000 |
| Saturday, January 1, 2022 | 2676000000 | 325998000 |
| Sunday, January 1, 2023 | 3297000000 | 332540000 |
| Monday, January 1, 2024 | 3790000000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Genmab A/S and PTC Therapeutics, Inc., from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, PTC Therapeutics, Inc. has maintained a more modest growth trajectory, with expenses rising by about 640%, reaching $332 million in 2023. This comparison highlights the diverse strategies employed by biotech firms in managing operational costs, with Genmab A/S focusing on rapid scaling, while PTC Therapeutics, Inc. opts for steady growth.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.